{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T04:53:16Z","timestamp":1767156796589,"version":"build-2065373602"},"reference-count":58,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T00:00:00Z","timestamp":1755129600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Background\/Objectives: Influenza represents a significant burden on global public health, and vaccination is the most effective strategy to reduce it. The large investment in vaccination programs and the need for adjustments in vaccine serotypes are important reasons for evaluating the influenza vaccine\u2019s efficacy every year. Establishing a relationship between immunogenicity data and efficacy is also crucial for predicting the efficacy of a vaccine during its development. Antibody response measurement is one of the most common methods for evaluating immunogenicity, particularly in vaccines and biologics. The aim of this systematic review was to define a model that relates the immunogenicity of a given vaccine to its efficacy, based on hemagglutination inhibition titer levels. Methods: To achieve this goal, information was gathered from articles linking immunogenicity with the efficacy of the influenza vaccine in the Medline and Scopus databases. Different mathematical models were developed and applied to assess the relationship between HAI titers and the effectiveness of the flu vaccine. This analysis was conducted for the various existing vaccines, for the different influenza virus strains, and for their efficacy in paediatric populations. Results: The r2 obtained ranged from 0.2579 to 0.966, which points to the importance of this immunological factor in the efficacy of the influenza vaccine. Conclusions: The efficacy values for titer level 40 confirm the validity of the data provided by Hobson.<\/jats:p>","DOI":"10.3390\/vaccines13080859","type":"journal-article","created":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T15:44:21Z","timestamp":1755186261000},"page":"859","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Immunogenicity as a Predictor of Influenza Vaccine Efficacy: A Systematic Review"],"prefix":"10.3390","volume":"13","author":[{"given":"Andr\u00e9 Miguel","family":"Martins","sequence":"first","affiliation":[{"name":"LAQV\/REQUIMTE, Escola Superior de Sa\u00fade, Instituto Polit\u00e9cnico do Porto, Rua Dr. Ant\u00f3nio Bernardino de Almeida, 4200-072 Porto, Portugal"}]},{"given":"Luis F\u00e9lix","family":"Valero Juan","sequence":"additional","affiliation":[{"name":"Medicina Preventiva y Salud P\u00fablica, Facultad de Medicina, Universidad de Salamanca, 37007 Salamanca, Spain"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5020-5942","authenticated-orcid":false,"given":"Marlene","family":"Santos","sequence":"additional","affiliation":[{"name":"LAQV\/REQUIMTE, Escola Superior de Sa\u00fade, Instituto Polit\u00e9cnico do Porto, Rua Dr. Ant\u00f3nio Bernardino de Almeida, 4200-072 Porto, Portugal"},{"name":"Molecular Oncology & Viral Pathology, IPO-Porto Research Center, Portuguese Institute of Oncology, Rua Dr. Ant\u00f3nio Bernardino de Almeida, 4200-072 Porto,  Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0474-1397","authenticated-orcid":false,"given":"Jo\u00e3o P.","family":"Martins","sequence":"additional","affiliation":[{"name":"Escola Superior de Sa\u00fade, Instituto Polit\u00e9cnico do Porto, Rua Dr. Ant\u00f3nio Bernardino de Almeida, 4200-072 Porto, Portugal"},{"name":"CEAUL\u2014Centro de Estat\u00edstica e Aplica\u00e7\u00f5es, Faculdade de Ci\u00eancias, Universidade de Lisboa, 1749-016 Lisboa, Portugal"}]}],"member":"1968","published-online":{"date-parts":[[2025,8,14]]},"reference":[{"key":"ref_1","unstructured":"European Centre for Disease Prevention and Control (2020). Systematic Review of the Efficacy, Effectiveness and Safety of Newer and Enhanced Seasonal Influenza Vaccines for the Prevention of Laboratory-Confirmed Influenza in Individuals Aged 18 Years and Over, Stockholm."},{"key":"ref_2","unstructured":"WHO The Global Influenza Surveillance and Response System. Available online: https:\/\/www.who.int\/initiatives\/global-influenza-surveillance-and-response-system."},{"key":"ref_3","unstructured":"(2020). WHO. WHO Regional Office for Europe Recommendations on Influenza Vaccination for the 2020\/2021 Season During the Ongoing COVID-19 Pandemic, WHO Regional Office for Europe."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.ijid.2020.02.040","article-title":"Who and When to Vaccinate Against Influenza","volume":"93","author":"Buchy","year":"2020","journal-title":"Int. J. Infect. Dis."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/978-1-4614-0980-9_9","article-title":"Influenza Virus Entry","volume":"Volume 726","author":"Rossmann","year":"2012","journal-title":"Viral Molecular Machines"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.tim.2018.05.013","article-title":"Influenza Virus","volume":"26","author":"Hutchinson","year":"2018","journal-title":"Trends Microbiol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"D49","DOI":"10.1016\/j.vaccine.2008.07.039","article-title":"The Biology of Influenza Viruses","volume":"26","author":"Bouvier","year":"2008","journal-title":"Vaccine"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s12098-016-2232-x","article-title":"Influenza in Children","volume":"84","author":"Kumar","year":"2017","journal-title":"Indian J. Pediatr."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e2014","DOI":"10.1002\/rmv.2014","article-title":"Influenza Vaccine: Where Are We and Where Do We Go?","volume":"29","author":"Keshavarz","year":"2019","journal-title":"Rev. Med. Virol."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Kumar, A., Meldgaard, T.S., and Bertholet, S. (2018). Novel Platforms for the Development of a Universal Influenza Vaccine. Front. Immunol., 9.","DOI":"10.3389\/fimmu.2018.00600"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1002\/biot.201400393","article-title":"Emerging Influenza Viruses and the Prospect of a Universal Influenza Virus Vaccine","volume":"10","author":"Krammer","year":"2015","journal-title":"Biotechnol. J."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"373","DOI":"10.3390\/vaccines3020373","article-title":"Influenza Vaccination Strategies: Comparing Inactivated and Live Attenuated Influenza Vaccines","volume":"3","author":"Sridhar","year":"2015","journal-title":"Vaccines"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1017\/S0022172400022610","article-title":"The Role of Serum Haemagglutination-Inhibiting Antibody in Protection Against Challenge Infection with Influenza A2 and B Viruses","volume":"70","author":"Hobson","year":"1972","journal-title":"Epidemiol. Infect."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.3201\/eid1508.081754","article-title":"Reproducibility of Serologic Assays for Influenza Virus A (H5N1)","volume":"15","author":"Stephenson","year":"2009","journal-title":"Emerg. Infect. Dis."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"4113","DOI":"10.1016\/j.vaccine.2012.02.077","article-title":"Enhancing the Reproducibility of Serological Methods Used to Evaluate Immunogenicity of Pandemic H1N1 Influenza Vaccines\u2014An Effective EU Regulatory Approach","volume":"30","author":"Wagner","year":"2012","journal-title":"Vaccine"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.vaccine.2011.11.019","article-title":"Reproducibility of Serology Assays for Pandemic Influenza H1N1: Collaborative Study to Evaluate a Candidate WHO International Standard","volume":"30","author":"Wood","year":"2012","journal-title":"Vaccine"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Martins, J.P., Santos, M., Martins, A., Felgueiras, M., and Santos, R. (2023). Seasonal Influenza Vaccine Effectiveness in Persons Aged 15\u201364 Years: A Systematic Review and Meta-Analysis. Vaccines, 11.","DOI":"10.3390\/vaccines11081322"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/S1473-3099(16)00129-8","article-title":"Variable Influenza Vaccine Effectiveness by Subtype: A Systematic Review and Meta-Analysis of Test-Negative Design Studies","volume":"16","author":"Belongia","year":"2016","journal-title":"Lancet Infect. Dis."},{"key":"ref_19","unstructured":"Rohatgi, A. WebPlotDigitizer User Manual Version 3.4. Available online: https:\/\/web.eecs.utk.edu\/~dcostine\/personal\/PowerDeviceLib\/DigiTest\/index.html."},{"key":"ref_20","unstructured":"R Core Team The R Project for Statistical Computing. Available online: http:\/\/www.R-project.org\/."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"498","DOI":"10.6339\/21-JDS1020","article-title":"Shape-Restricted Regression Splines with R Package Splines2","volume":"19","author":"Wang","year":"2021","journal-title":"J. Data Sci."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1080\/01621459.2016.1180986","article-title":"Smoothing Parameter and Model Selection for General Smooth Models (with Discussion)","volume":"111","author":"Wood","year":"2016","journal-title":"J. Am. Stat. Assoc."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: A Tool for Assessing Risk of Bias in Non-Randomised Studies of Interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1097\/INF.0b013e3182367662","article-title":"Hemagglutination Inhibition Antibody Titers as a Correlate of Protection for Inactivated Influenza Vaccines in Children","volume":"30","author":"Black","year":"2011","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"ofab477","DOI":"10.1093\/ofid\/ofab477","article-title":"Association Between Hemagglutination Inhibition Antibody Titers and Protection Against Reverse-Transcription Polymerase Chain Reaction\u2013Confirmed Influenza Illness in Children 6\u201335 Months of Age: Statistical Evaluation of a Correlate of Protection","volume":"9","author":"Danier","year":"2022","journal-title":"Open Forum Infect. Dis."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Gilbert, P.B., Fong, Y., Juraska, M., Carpp, L.N., Monto, A.S., Martin, E.T., and Petrie, J.G. (2019). HAI and NAI Titer Correlates of Inactivated and Live Attenuated Influenza Vaccine Efficacy. BMC Infect. Dis., 19.","DOI":"10.1186\/s12879-019-4049-5"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1016\/S0264-410X(96)00153-3","article-title":"The Hemagglutination Inhibition Antibody Responses to an Inactivated Influenza Vaccine Among Healthy Adults: With Special Reference to the Prevaccination Antibody and Its Interaction with Age","volume":"14","author":"Hirota","year":"1996","journal-title":"Vaccine"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1093\/infdis\/jiv195","article-title":"Antibody to Influenza Virus Neuraminidase: An Independent Correlate of Protection","volume":"212","author":"Monto","year":"2015","journal-title":"J. Infect. Dis."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1093\/infdis\/jit372","article-title":"Estimation of the Association Between Antibody Titers and Protection Against Confirmed Influenza Virus Infection in Children","volume":"208","author":"Ng","year":"2013","journal-title":"J. Infect. Dis."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1093\/infdis\/jir661","article-title":"Influenza Hemagglutination-Inhibition Antibody Titer as a Correlate of Vaccine-Induced Protection","volume":"204","author":"Ohmit","year":"2011","journal-title":"J. Infect. Dis."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1093\/infdis\/jiu186","article-title":"Association Between Antibody Titers and Protection Against Influenza Virus Infection Within Households","volume":"210","author":"Tsang","year":"2014","journal-title":"J. Infect. Dis."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Coudeville, L., Bailleux, F., Riche, B., Megas, F., Andre, P., and Ecochard, R. (2010). Relationship Between Haemagglutination-Inhibiting Antibody Titres and Clinical Protection Against Influenza: Development and Application of a Bayesian Random-Effects Model. BMC Med. Res. Methodol., 10.","DOI":"10.1186\/1471-2288-10-18"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"405","DOI":"10.4161\/hv.22908","article-title":"Correlates of Protection to Influenza Virus, Where Do We Go from Here?","volume":"9","author":"Cox","year":"2013","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1086\/315323","article-title":"Correlates of Immune Protection Induced by Live, Attenuated, Cold-Adapted, Trivalent, Intranasal Influenza Virus Vaccine","volume":"181","author":"Belshe","year":"2000","journal-title":"J. Infect. Dis."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Perego, G., Vigezzi, G.P., Cocciolo, G., Chiappa, F., Salvati, S., Balzarini, F., Odone, A., Signorelli, C., and Gianfredi, V. (2021). Safety and Efficacy of Spray Intranasal Live Attenuated Influenza Vaccine: Systematic Review and Meta-Analysis. Vaccines, 9.","DOI":"10.3390\/vaccines9090998"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1093\/cid\/ciz358","article-title":"Successes and Failures of the Live-Attenuated Influenza Vaccine: Can We Do Better?","volume":"70","author":"Matrajt","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"a038653","DOI":"10.1101\/cshperspect.a038653","article-title":"Live Attenuated Cold-Adapted Influenza Vaccines","volume":"11","author":"Subbarao","year":"2021","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1093\/infdis\/jiae122","article-title":"Hemagglutination Inhibition Antibody Titers as Mediators of Influenza Vaccine Efficacy Against Symptomatic Influenza A(H1N1), A(H3N2), and B\/Victoria Virus Infections","volume":"230","author":"Lim","year":"2024","journal-title":"J. Infect. Dis."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Skowronski, D.M., Moser, F.S., Janjua, N.Z., Davoudi, B., English, K.M., Purych, D., Petric, M., and Pourbohloul, B. (2013). H3N2v and Other Influenza Epidemic Risk Based on Age-Specific Estimates of Sero-Protection and Contact Network Interactions. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0054015"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Beran, J., Wertzova, V., Honegr, K., Kaliskova, E., Havlickova, M., Havlik, J., Jirincova, H., Van Belle, P., Jain, V., and Innis, B. (2009). Challenge of Conducting a Placebo-Controlled Randomized Efficacy Study for Influenza Vaccine in a Season with Low Attack Rate and a Mismatched Vaccine B Strain: A Concrete Example. BMC Infect. Dis., 9.","DOI":"10.1186\/1471-2334-9-2"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1093\/cid\/ciy759","article-title":"Influenza Hemagglutination-Inhibition Antibody Titer as a Mediator of Vaccine-Induced Protection for Influenza B","volume":"68","author":"Cowling","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/S1473-3099(11)70295-X","article-title":"Efficacy and Effectiveness of Influenza Vaccines: A Systematic Review and Meta-Analysis","volume":"12","author":"Osterholm","year":"2012","journal-title":"Lancet Infect. Dis."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"126408","DOI":"10.1016\/j.vaccine.2024.126408","article-title":"Advancing Influenza Vaccines: A Review of next-Generation Candidates and Their Potential for Global Health Impact","volume":"42","author":"Taaffe","year":"2024","journal-title":"Vaccine"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1056\/NEJMoa1315727","article-title":"Efficacy of High-Dose Versus Standard-Dose Influenza Vaccine in Older Adults","volume":"371","author":"DiazGranados","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"5027","DOI":"10.1016\/j.vaccine.2014.07.013","article-title":"Comparison of the Safety and Immunogenicity of an MF59\u00ae-Adjuvanted with a Non-Adjuvanted Seasonal Influenza Vaccine in Elderly Subjects","volume":"32","author":"Frey","year":"2014","journal-title":"Vaccine"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.vaccine.2016.12.011","article-title":"Effectiveness of MF59-Adjuvanted Seasonal Influenza Vaccine in the Elderly: A Systematic Review and Meta-Analysis","volume":"35","author":"Domnich","year":"2017","journal-title":"Vaccine"},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Memoli, M.J., Shaw, P.A., Han, A., Czajkowski, L., Reed, S., Athota, R., Bristol, T., Fargis, S., Risos, K., and Powers, J.H. (2016). Evaluation of Antihemagglutinin and Antineuraminidase Antibodies as Correlates of Protection in an Influenza A\/H1N1 Virus Healthy Human Challenge Model. mBio, 7.","DOI":"10.1128\/mBio.00417-16"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"S75","DOI":"10.1093\/infdis\/jiz017","article-title":"Neuraminidase, the Forgotten Surface Antigen, Emerges as an Influenza Vaccine Target for Broadened Protection","volume":"219","author":"Eichelberger","year":"2019","journal-title":"J. Infect. Dis."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/s41573-019-0056-x","article-title":"Next-Generation Influenza Vaccines: Opportunities and Challenges","volume":"19","author":"Wei","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2616","DOI":"10.1016\/S0264-410X(03)00040-9","article-title":"Induction of Influenza Type A Virus-Specific Resistance by Immunization of Mice with a Synthetic Multiple Antigenic Peptide Vaccine That Contains Ectodomains of Matrix Protein 2","volume":"21","author":"Mozdzanowska","year":"2003","journal-title":"Vaccine"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.antiviral.2008.06.002","article-title":"Therapeutic Potential of a Fully Human Monoclonal Antibody Against Influenza A Virus M2 Protein","volume":"80","author":"Wang","year":"2008","journal-title":"Antivir. Res."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1186\/1743-422X-7-351","article-title":"Conserved Epitopes of Influenza A Virus Inducing Protective Immunity and Their Prospects for Universal Vaccine Development","volume":"7","year":"2010","journal-title":"Virol. J."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1038\/nm.3350","article-title":"Cellular Immune Correlates of Protection Against Symptomatic Pandemic Influenza","volume":"19","author":"Sridhar","year":"2013","journal-title":"Nat. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1038\/nm.2612","article-title":"Preexisting Influenza-Specific CD4+ T Cells Correlate with Disease Protection Against Influenza Challenge in Humans","volume":"18","author":"Wilkinson","year":"2012","journal-title":"Nat. Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"e1491","DOI":"10.1002\/cti2.1491","article-title":"Fighting Flu: Novel CD8+ T-Cell Targets Are Required for Future Influenza Vaccines","volume":"13","author":"Leong","year":"2024","journal-title":"Clin. Trans. Immunol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1146\/annurev.immunol.17.1.51","article-title":"Immunodominance in major histocompatibility complex class I\u2013restricted T lymphocyte responses","volume":"17","author":"Yewdell","year":"1999","journal-title":"Annu. Rev. Immunol."},{"key":"ref_57","first-page":"3478","article-title":"Memory T Cells Established by Seasonal Human Influenza A Infection Cross-React with Avian Influenza A (H5N1) in Healthy Individuals","volume":"118","author":"Lee","year":"2008","journal-title":"J. Clin. Investig."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.virusres.2011.09.022","article-title":"Immune Responses to Influenza Virus Infection","volume":"162","author":"Kreijtz","year":"2011","journal-title":"Virus Res."}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/13\/8\/859\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:26:58Z","timestamp":1760034418000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/13\/8\/859"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,14]]},"references-count":58,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,8]]}},"alternative-id":["vaccines13080859"],"URL":"https:\/\/doi.org\/10.3390\/vaccines13080859","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,14]]}}}